Gilead Announces Long-term Safety And Efficacy Data For Seladelpar In Primary Biliary Cholangitis

(RTTNews) – Gilead Sciences, Inc. (GILD) Wednesday announced positive results from two-year interim analysis of the ongoing ASSURE study evaluating the company’s investigational drug seladelpar for the treatment of primary biliary cholangitis (PBC), a rare, chronic inflammatory l

admin